Slides
Page 1
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol ASX: CUV | Nasdaq: CUVL | Börse Frankfurt: UR9 U.S. Expansion Supported by Strong Foundation Financial Year Ended 30 June 2026 Investor Briefings: 27 August – 4 September 2026
Page 2
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol Forward - looking statement CLINUVEL GROUP This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intend,” “likely,” “may,” “objective,” “potential,” “plan,” “predict,” “project,” “seek,” “should,” “will” and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include but are not limited to risks relating to: our ability to develop and commercialise pharmaceutical products; pandemics, epidemics, public health emergencies, geopolitical conflicts, trade restrictions, natural disasters and other disruptions affecting global supply chains, including our ability to develop, manufacture, market and sell biopharmaceutical and PhotoCosmetic products; competition for our products, especially SCENESSE® (afamelanotide 16mg), CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed and characterised by us as PhotoCosmetics; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, CYACÊLLE, PRÉNUMBRA®, NEURACTHEL® or products developed as PhotoCosmetics which may lead to the Company being unable to launch, supply or serve its commercial markets, special access programs and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare, Medicaid, and U.S. Department of Veteran’s Affairs) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology, cosmetic and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry, cosmetic industry and related industries; potential changes to tax liabilities or legislation; environmental risks including the risk factors described in the Company's Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission, together with the Company's announcements lodged with the Australian Securities Exchange. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation except as required by applicable law, the rules of the Australian Securities Exchange, the U.S. Securities and Exchange Commission, Nasdaq, or other applicable regulatory requirements, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.
Page 3
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol CONSOLIDATED ENTITY1 30 June 2026 Change Revenues2 A$94m -1% Revenues plus Interest and Other Income A$101m -4% Expenses A$53m -0.5% Net Profit Before Income Tax Expense A$48m -8% Net Profit After Income Tax Expense A$34m -6% Cash Reserves3 A$252m +12% Basic Earnings per Share A$0.68 -6% Net Tangible Assets Backing per Share A$5.35 +12% Dividend per Share Declared A$0.05 Stable FY2026 Financial performance • disciplined and balanced approach • second consecutive year of $100m+ total revenue • 10 consecutive annual profits • 9 consecutive annual dividends • FX translation of US$ term deposits resulted in unrealised loss of $4m impacting net profit • RD&I growth through controlled expenses • $12m of FY2026 income tax prepaid 1. All figures released to the Australian Securities Exchange in Australian dollars (A$) for financial year ended 30 June 2026. 2. Revenues from ordinary activities, excluding interest and other income. 3. Cash Reserves equal Cash and cash equivalents plus Cash held in term deposits (i.e. short-term investments).
Page 4
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol FY2026 Profitability SCENESSE® in EPP1 – profitability 0 10 20 30 40 50 60 -60 -40 -20 0 20 40 60 80 100 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Year Ending 30 June (A$m) Revenues (LHS) Expenses (LHS) Net Profit Before Tax (RHS) Net Profit After Tax (RHS) 1. Erythropoietic protoporphyria. revenues growth over a decade 10-year CAGR 31% expenses growth well controlled 10-year CAGR 18% net profit margin 36% reinvestment RD&I 34% return on equity 13%
Page 5
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol FY2026 Expenses • Expenses well controlled at $A53m, lower than 5- year average forecast expenditures. • Largest allocation of resources to R&D at 34% of total expenses; reduction reflects cyclical timing of CUV105 clinical program completion • Rise in General and Admin. reflects one-off Nasdaq listing costs • Communications and Marketing lower as discretionary costs reduced 0 7 14 21 A$m FY2025 FY2026 Communications and Marketing –1.2% General and Administrative +15.7% Research and Development -12.6% Cost of Revenues +6.8% 8.9 8.4 9.3 11.2 20.7 18.1 14.8 15.8
Page 6
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol 1. Cash Reserves finance key initiatives through re-investment 2. Investment in infrastructure - expansion of Singaporean RD&I facility - refurbishment of Egham, UK, office 3. Establishing manufacturing & supply chain integration 4. Development of VLRX-L next-generation peptide platform 5. Balance Sheet strength provides resilience & optionality Year ended 30 June 2025 2026 Total Assets A$272m A$295m +9% Total Liabilities • mainly trade creditors & tax • debt-free A$31m A$22m -28% Cash Reserves 1 A$224m A$252m +12% FY2026 Strong balance sheet 1. Cash Reserves equal Cash and cash equivalents plus Cash held in term deposits (i.e. short-term investments). 0 50 100 150 200 250 300 Assets Liabilities Assets & liabilities (A$m) FY2022 FY2023 FY2024 FY2025 FY2026 0 40 80 120 160 200 240 280 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 Cash reserves (A$m)
Page 7
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol Building a sustainable, integrated biopharmaceutical company Profitable, focused, disciplined Milestones Incorporated in Australia upon acquisition of afamelanotide technology 1999 Listed on Australian Securities Exchange; trades as CUV 2001 Established ADR Level I, on U.S. OTC; Commenced trading on Börse Frankfurt (UR9) 2004 2006 Strategic refocus “one drug for one indication” 2016 SCENESSE® distribution EU 2020 SCENESSE® distribution USA 2021/22 Expansion of Product Range & Clinical Program; First adolescent EPP patient treated 2025 First phase III vitiligo trial fully recruited; EU maximum recommended dose removed 2026 melanocortins, chemistry, pharmacology indications, clinical formulation development manufacturing in-licensing, M&A Ten years profitable • distribution of SCENESSE® for EPP • Europe, U.S.A., Israel, UK, Canada Strong balance sheet • zero debt • cash reserves A$252m (US$171m) • >4 year OPEX cash runway Nine years of dividends – FY2026 returning 9% of cash reserves increase High potential pipeline HQ – transitioning from Australia to U.S.A. Principal operations – U.S.A., Europe, UK, Singapore Commenced ADS Level II, traded on Nasdaq (CUVL); SCENESSE® distribution Canada
Page 8
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol Expanding American presence Significant opportunity to treat patients in need Increased American investor interest • Phase III vitiligo studies – systemic Rx [not immune suppressive] • SCENESSE® in EPP – direct distribution across 129 U.S. and 5 Canadian centers – 190 targeted (2027) • U.S. comprises >43% of global EPP revenues • Nasdaq uplisting (ADS, Level II) – completed 20 July 2026 • Board considering full listing on Nasdaq / delisting ASX • Head Office relocation to U.S. – from 1 January 2027 • Increase U.S. management team – 2027 8
Page 9
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol Commercial product and pipeline: melanocortins NEURACTHEL® instant – IS, MS 1 1st European filing H2 2026 NEURACTHEL® modified release – CNS 1 SCENESSE® (afamelanotide 16 mg) in variegate porphyria SCENESSE® (afamelanotide 16 mg) in adolescent and adult vitiligo Topline results CUV105 H2 2026 SCENESSE® (afamelanotide 16 mg) in adolescent EPP Filing H2 2027 SCENESSE® (afamelanotide 16 mg) in adult EPP EEA, UK, CH, U.S.A., ISL, CAN, AUS Preclinical Phase I Phase II Phase III Commercial VLRX–L controlled-release peptide platform Other platforms TBA Further preclinical results 2027 1. IS= infantile spasms; MS = multiple sclerosis; CNS = central nervous system. Preclinical program ongoing
Page 10
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol Future outlook Foundation of 20 years Products, indications & healthcare solutions • 2 pharmaceutical products • 5 conditions • 3 PhotoCosmetic product lines Advancing RD&I • novel sustained-release liquid peptide formulations (VLRX-L) Capital management • disciplined deployment of capital • no dilutive capital raisings – 10 years • debt free TAM and penetration figures are in U.S. dollars (US$). 1. EPP revenues in FY26. 2. CLINUVEL estimates, Vitiligo is year 1 and 2 in U.S.A.. Vitiligo Phase III top line data expected December 2026 is a key value driver MELANOCORTIN HOUSE TAM >US$300m Porphyria (EPP & VP) CUV: FY26 US$64m1 TAM >US$6.2b PhotoCosmetics CUV: US$50m2 TAM >US$4.5b Vitiligo CUV: US$490–570m2 TAM >US$1.3b ACTH CUV: US$150m2
Page 11
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol CY2026 H1 H2 CY2027 H1 H2 SCENESSE® Health Canada: Marketing Authorization decision √ EMA filing SCENESSE®: adolescent use in EPP Phase III, CUV105 vitiligo AAD’26 cases presented √ Top line results (Dec ‘26) Complete results Phase III, CUV107 vitiligo EMA Scientific Advice √ Start recruitment (Nov ‘26) FDA vitiligo meeting Recruitment completed ACTH–NEURACTHEL® EU: 1st filing(s) for marketing authorisation VLRX–L Liquid controlled-release formulation first preclinical results √ Pipeline New peptides in liquid controlled- release preclinical data RD&I VALLAURIX Singapore: complete construction of expanded RD&I Centre Finance, commercial FY’26 Half Year Results (31 Dec ‘25) √ FY’26 Financial Year Results (30 Jun ‘26) √ FY’27 Half Year Results (31 Dec ‘26) FY’27 Financial Year Results (30 Jun ‘27) Commercial update EPP-Vitiligo √ SEC review: Nasdaq, ADR upgrade √ Calendar & catalysts Plans and expected timelines are subject to change as part of running an active business in a volatile operating environment. In addition, product development and clinical studies can experience delays and the time periods of assessment of regulatory submissions can vary.
Page 12
Navy-cuv Fossil Intense black Brass 66 Midnight Royal Cobalt Sky Imperial Emerald Burgundy Rosso Flame Sol ASX: CUV | Börse Frankfurt: UR9 | ADR Level II: CUVL Thank you Authorised for ASX release by the Managing Director on behalf of the Board of Directors of CLINUVEL PHARMACEUTICALS LTD Head of Investor Relations: Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD Investor Enquiries: https://www.clinuvel.com/investors/contact-us Level 22, 535 Bourke Street, Melbourne – Victoria, Australia, 3000 | T +61 3 9660 4900 | F +61 3 9660 4909 www.clinuvel.com